Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Jeffrey Albers sold 5,000 shares of the firm's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Kymera Therapeutics Price Performance
Shares of NASDAQ KYMR opened at $94.30 on Tuesday. The stock has a market capitalization of $6.78 billion, a PE ratio of -26.27 and a beta of 2.28. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $103.00. The business's fifty day moving average price is $62.19 and its 200-day moving average price is $50.50.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.19). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The firm had revenue of $2.76 million during the quarter, compared to analysts' expectations of $23.15 million. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms have recently issued reports on KYMR. B. Riley boosted their price target on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, October 24th. Royal Bank Of Canada assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, September 16th. They issued an "outperform" rating and a $70.00 price objective for the company. Mizuho assumed coverage on Kymera Therapeutics in a research report on Tuesday, October 21st. They set an "outperform" rating and a $81.00 target price on the stock. Barclays raised their price target on Kymera Therapeutics from $60.00 to $70.00 and gave the stock an "overweight" rating in a report on Wednesday, November 5th. Finally, UBS Group set a $90.00 price objective on Kymera Therapeutics and gave the stock a "buy" rating in a report on Wednesday, November 26th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of "Buy" and an average target price of $81.68.
Get Our Latest Analysis on Kymera Therapeutics
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC increased its holdings in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares during the period. PNC Financial Services Group Inc. grew its position in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after buying an additional 770 shares in the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after acquiring an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after acquiring an additional 815 shares in the last quarter.
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
